Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

Therapeutic Reaction of Dogs to (117mSn) Colloid Intraarticular Injection

Mareiy Anad Nuyr

Objective: To determine if a reprise intraarticular( IA) injection of a drum- 117m colloid radiosynoviorthesis( RSO) agent can be safely given in the same joint 12 months after an original injection for treatment of canine elbow osteoarthritis( OA), and to estimate the pain reduction effect of the reprise injection.

Methods and Materials: Nine customer possessed tykes with grade 1 or 2 elbow OA were given an IA injection of drum- 117m colloid in both elbows, one of which had been treated ≤ 12 months before with the same RSO device. Common fluid analysis at birth (BL) and 180 days following treatment, as well as urinalysis, CBC, and serum chemistry analysis of individual samples obtained at BL and 180 days, were used to determine treatment safety. At BL and 180 days, radiographs, computed tomography, and MRI reviews were obtained to see if the evolution of the complaint varied between elbows that received one injection or two.

Findings: All post-treatment CBC, clinical chemistry, and urinalysis findings fell below normal limits. An examination of the common fluid revealed a significant (P = 0.0411) decline in the likelihood of monocytes at 180 days, consistent with the drum-117m colloid mode of action of pro-inflammatory macrophage death at the injection site. The progression of OA in elbows that received one or two injections did not differ significantly.

Conclusion: The drum-117m colloid can potentially provide a long-lasting curative response in children with elbow OA when administered as a reprise injection 12 months after the initial injection.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.